October generally remains volatile on Wall Street. This year, volatility has gripped in U.S. stock markets from the beginning of this month. October’s volatility is expected to persist due to a better-than-expected jobs data for September, expectations of a Fed rate cut in a gradual fashion rather than more aggressive way, a jump in the yield of the benchmark 10-Year Treasury Note, intensified geopolitical conflict in the Middle East and the upcoming U.S. Presidential election on Nov. 5.Consequently, a hand ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Oct. 10, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises ADMA Biologics, Inc. (“ADMA Biologics” or “the Company”) (NASDAQ: ADMA) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. ADMA Biologics investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investors are encouraged to ...

BOSTON, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating ADMA Biologics, Inc. (Nasdaq: ADMA) for potential securities law violations. Investors who have lost money in their ADMA Biologics investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/adma.  What is this all about? On October 10, 2024, shares of ADMA Biologics, Inc. fell nearly 20% following the Company's after-market announcement that its i ...

The most recent trading session ended with Adma Biologics (ADMA) standing at $20.33, reflecting a -1.91% shift from the previouse trading day's closing. The stock trailed the S&P 500, which registered a daily gain of 0.71%. At the same time, the Dow added 1.03%, and the tech-heavy Nasdaq gained 0.6%.The the stock of infectious disease drug developer has risen by 19.84% in the past month, leading the Medical sector's loss of 3.33% and the S&P 500's gain of 6.41%.The upcoming earnings release of Adma Biologic ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:ADMA Biologics (ADMA) : This specialty immune globulin company which develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases, has seen the Zacks Consensus Estimate for its current year earnings increasing 40% over the last 60 days.Vertex (VERX) : This company which provides tax technology solutions for corporations in retail, leasing, communication and manufactu ...

I specialize in biotech and healthcare investment analysis, integrating clinical expertise with a solid foundation in business strategy. My approach leverages detailed risk-return charts and DCF analyses to clearly communicate the investment potential and associated risks. I advocate for a barbell portfolio strategy, with 90% allocated to secure assets such as Treasuries and broad-market ETFs, and 10% to high-alpha stocks. This balanced approach ensures that all recommendations are made within a context of ...

The latest trading session saw Adma Biologics (ADMA) ending at $19.44, denoting a -0.26% adjustment from its last day's close. This change lagged the S&P 500's 0.4% gain on the day. At the same time, the Dow added 0.62%, and the tech-heavy Nasdaq gained 0.6%.The the stock of infectious disease drug developer has risen by 13.05% in the past month, leading the Medical sector's loss of 2.27% and the S&P 500's gain of 1.71%.Market participants will be closely following the financial results of Adma Biologics in ...

ADMA Biologics, Inc.’s (ADMA) shares skyrocketed 76.2% in the past three months compared with the industry’s growth of 9.6%. The stock also hit a new 52-week high of $19.34 on Sept. 9.The stupendous rally can be attributed to the company’s impressive performance year to date. Sales in the first half increased 61%. Last month, the company also raised its annual guidance for 2024 and 2025 revenues and net income, based on the continuous growth of its unique and proprietary immunoglobulin, Asceniv.ADMA Outperf ...

RAMSEY, N.J. and BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced it will join the S&P SmallCap 600 index, effective prior to the open of trading on Monday, September 23, 2024. The S&P SmallCap 600 seeks to measure the small-cap segment of the U.S. equity market. "ADMA’s inclusion in the S&P SmallCap 600 index is a sig ...

After reaching an important support level, Adma Biologics (ADMA) could be a good stock pick from a technical perspective. ADMA surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.The 20-day simple moving average is a well-liked trading tool because it provides a look back at a stock's price over a 20-day period. Additionally, short-term traders find this SMA very beneficial, as it smooths out short-term price trends and shows more trend reversal signals than longer-term ...